Avagacestat BMS-708163 is a small-molecule inhibitor of gamma-secretase, an enzyme involved in the production of amyloid-beta (Aβ) peptides that play a critical role in the development of Alzheimer's disease. In this article, we will delve into the chemical properties of Avagacestat BMS-708163, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.
Chemical Properties
The chemical name of Avagacestat BMS-708163 is (S)-2-(2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenylamino)-N-(1-methyl-1H-pyrazol-5-yl)-4-((tetrahydrofuran-3-yl)oxy)butanamide. Its molecular formula is C24H29FN6O3 and formula weight is 468.53 g/mol. The CAS number of Avagacestat BMS-708163 is 1146699-66-2.
Top Ten Keywords and Synonyms
Synonyms:
Health Benefits
Avagacestat BMS-708163 has shown potential benefits in treating Alzheimer's disease and other neurodegenerative disorders by reducing the production of beta-amyloid protein, a hallmark of these diseases. It may also have applications in preventing cognitive impairment and memory loss associated with aging.
Potential Effects
Avagacestat BMS-708163 primarily acts as an inhibitor of gamma-secretase, an enzyme that plays a critical role in the production of beta-amyloid protein, which is implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. By inhibiting gamma-secretase, Avagacestat BMS-708163 can reduce the production of beta-amyloid protein, thus slowing down the progression of Alzheimer's disease and other neurodegenerative disorders.
Product Mechanism
Gamma-secretase is an enzyme complex that cleaves the transmembrane domains of several proteins, including amyloid precursor protein (APP), to produce beta-amyloid protein. Beta-amyloid protein is thought to play a critical role in the development of Alzheimer's disease and other neurodegenerative disorders. Avagacestat BMS-708163 selectively inhibits gamma-secretase, thereby reducing the production of beta-amyloid protein and ultimately slowing down the progression of Alzheimer's disease and other neurodegenerative disorders.
Safety
Avagacestat BMS-708163 has demonstrated a good safety profile in clinical studies. However, it may interact with other medications and cause adverse reactions in some patients. Patients should consult their healthcare provider before using Avagacestat BMS-708163.
Side Effects
Common side effects of Avagacestat BMS-708163 include nausea, headaches, and gastrointestinal disturbances. Rare but serious side effects include liver dysfunction and allergic reactions. Patients should seek medical attention immediately if they experience any serious side effects or symptoms.
Dosing Information
The recommended dose of Avagacestat BMS-708163 for the treatment of Alzheimer's disease is 50 mg once daily. The optimal dose and duration of treatment for other neurodegenerative disorders are unknown, and further research is needed to establish safe and effective dosing regimens.
Conclusion
Avagacestat BMS-708163 is a promising gamma-secretase inhibitor with potential therapeutic applications in treating various neurodegenerative disorders such as Alzheimer's disease. Its mechanism of action involves reducing the production of beta-amyloid protein, which is implicated in the pathogenesis of these diseases. While it has demonstrated a good safety profile in clinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, Avagacestat BMS-708163 has great potential as a novel therapeutic agent in the treatment of various neurodegenerative disorders.
